Marisa Wexler, MS,  senior science writer—

An approved therapy for multiple sclerosis (MS), called Gilenya (fingolimod), was effective at treating a man who had a rare combination of MS and hereditary angioedema (HAE), researchers in Greece have found. “We report [a] case study of a patient with concurrence of HAE and MS, discussing…

A common over-the-counter painkiller induced two allergic reactions — one of them leading to angioedema, and another to skin lesions — in a case study of a 41-year-old man. The report, “Angioedema and fixed drug eruption simultaneously induced by naproxen sodium: A rare clinical entity,” was…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

A man who had been treated with the blood pressure medication losartan for 20 years experienced sudden angioedema after upping the medication’s dose, according to a recent case report. “This is the first documented case of angioedema presenting in a dose-dependent manner with losartan use. We hope that our…

Takhzyro (lanadelumab) has been approved in Japan to prevent acute swelling attacks in people, 12 and older, with hereditary angioedema (HAE). An estimated 2,000 to 3,000 people with HAE live in Japan, but fewer than 500 have been diagnosed due to a lack of awareness, according to…

Donidalorsen significantly reduced swelling attacks and improved quality of life in people with hereditary angioedema (HAE) treated in a Phase 2 trial. Full trial results were detailed in the study, “Inhibition of Prekallikrein for Hereditary Angioedema,” published in The New England Journal of Medicine. The study…

Astria Therapeutics is gearing up to request permission for clinical testing in the U.S. of STAR-0215, its experimental therapy to prevent swelling attacks in hereditary angioedema (HAE). The company is expected to submit a formal request — in the form of an investigational new drug application — to the…

KalVista Pharmaceuticals has launched a Phase 3 trial, called KONFIDENT, to test the safety and effectiveness of KVD900, an experimental oral and on-demand treatment for swelling attacks in people with hereditary angioedema (HAE). “Beginning the KONFIDENT trial represents a major milestone for KalVista,” Andrew Crockett, the company’s…

Special care must be taken with surgeries under general anesthesia in people with hereditary angioedema (HAE) to avoid dangerous swelling in the throat. A trio of researchers in Korea highlighted these considerations in the study “An anesthetic experience of hereditary angioedema type I patient undertook total…

People with hereditary angioedema (HAE) commonly have histories of cancer, which raises the possibility that it might predispose a person to develop cancer. These findings were reported in the study “Malignancy and immune disorders in patients with hereditary angioedema,” published in the journal Allergy, Asthma…